J Korean Neuropsychiatr Assoc.  2019 Feb;58(1):29-37. 10.4306/jknpa.2019.58.1.29.

The Long-Acting Injectable Antipsychotics in Clinical Practice

• Lee K

• KMID: 2439025
• DOI: http://doi.org/10.4306/jknpa.2019.58.1.29

Abstract

Symptomatic relapse is observed frequently and often associated with social and/or occupational decline that can be difficult to reverse in patients with schizophrenia. Several atypical antipsychotics, including risperidone, olanzapine, paliperidone, and aripiprazole, have become available as long-acting injectable antipsychotics (LAIs), and new evidence has been accumulating. LAIs appear to have a significant role in at least a group of schizophrenia patients. Improving the adherence, continuous availability, managing changes in receptor sensitivity, and lowering the requirement of cumulative doses are some of the major advantages of LAIs. Patients with first episode psychosis, dopamine super-sensitivity syndromes, and comorbid substance abuse might particularly benefit. Delaying the initiation of LAI until the establishment of non-adherence is not recommended. The results of clinical trials comparing LAIs with oral antipsychotics (OAPs) are inconsistent because they are influenced considerably by the study design. On the other hand, several barriers to LAIs use in current practice include clinical lack of knowledge, and negative attitudes about LAIs. This article tries to help clinicians better characterize the role of LAIs in the treatment of schizophrenia.

Keyword

Schizophrenia; Long-acting injections; Antipsychotics; Medication adherence

MeSH Terms

Antipsychotic Agents*
Aripiprazole
Dopamine
Hand
Humans
Medication Adherence
Paliperidone Palmitate
Psychotic Disorders
Recurrence
Risperidone
Schizophrenia
Substance-Related Disorders
Antipsychotic Agents
Aripiprazole
Dopamine
Paliperidone Palmitate
Risperidone

Reference

1. Agid O, Foussias G, Remington G. Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention. Expert Opin Pharmacother. 2010; 11:2301–2317.

2. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353:1209–1223.

3. Johnson DA. Historical perspective on antipsychotic long-acting injections. Br J Psychiatry Suppl. 2009; 52:S7–S12.

4. Naber D, Lambert M. The CATIE and CUtLASS studies in schizophrenia. CNS Drugs. 2009; 23:649–659.

5. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide chohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011; 168:603–609.

6. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long acting atypical antipsychotic. Am J Psychiatry. 2003; 160:1125–1132.

7. Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca PM, Chrzanowski W, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry. 2003; 64:1250–1257.

8. Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan P, Eriksson L, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol. 2005; 15:111–117.

9. Rosenheck RA, Krystal JH, Lew R, Barnett PG, Fiore L, Valley D, et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med. 2011; 364:842–851.

10. Rauch AS, Fleischhacker WW. Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective. CNS Drugs. 2013; 27:637–652.

11. Bushe CJ, Falk D, Anand E, Casillas M, Perrin E, Chhabra-Khanna R, et al. Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice. BMC Psychiatry. 2015; 15:65.

12. Alphs L, Bossie CA, Sliwa JK, Fu DJ, Ma YW, Hulihan J. Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics. Neuropsychiatr Dis Treat. 2013; 9:341–350.

13. Fu DJ, Bossie CA, Kern Sliwa J, Ma YW, Alphs L. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens. Clin Schizophr Relat Psychoses. 2014; 8:101–109.

14. Fu DJ, Bossie CA, Sliwa JK, Ma YW, Alphs L. Paliperidone palmitate versus oral risperidone and risperidone longacting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison. Int Clin Psychopharmacol. 2014; 29:45–55.

15. Berwaerts J, Liu Y, Gopal S, Nuamah I, Xu H, Savitz A, et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2015; 72:830–839.

16. Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Janik A, et al. Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority study. Int J Neuropsychopharmacol. 2016; 19:pyw018.

17. Kane JM, Sanchez R, Perry PP, Jin N, Johnson BR, Forbes RA, et al. Aripirazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012; 73:617–624.

18. Fleischhacker WW, Sanchez R, Perry PP, Jin N, Peters-Strickland T, Johnson BR, et al. Aripiprazole oncemonthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. Br J Psychiatry. 2014; 205:135–144.

19. Ishigooka J, Nakamura J, Fujii Y, Iwata N, Kishimoto T, Iyo M, et al. Efficacy and safety of aripiprazole oncemonthly in Asian patients with schizophrenia: a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole. Schizophr Res. 2015; 161:421–428.

20. Naber D, Hansen K, Forray C, Baker RA, Sapin C, Beillat M, et al. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophr Res. 2015; 168:498–504.

21. Aggarwal A, Gopalakrishna G, Lauriello J. Aripiprazole lauroxil long-acting injectable: the latest addition to second-generation long-acting agents. Clin Schizophr Relat Psychoses. 2016; 10:58–63.

22. Meltzer HY, Risinger R, Nasrallah HA, Du Y, Zummo J, Corey L, et al. A randomized, doubleblind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. J Clin Psychiatry. 2015; 76:1085–1090.

23. Correll CU, Citrome L, Haddad PM, Lauriello J, Olfson M, Calloway SM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016; 77:suppl 3. 1–24.

24. Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2014; 40:192–213.

25. Ostuzzi G, Bighelli I, So R, Furukawa TA, Barbui C. Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies. Schizophr Res. 2017; 183:10–21.

26. Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013; 74:957–965.

27. Haddad PM, Tiihonen J, Haukka J, Taylor M, Patel MX, Korhonen P. The place of observational studies in assessing the effectiveness of depot antipsychotics. Schizophr Res. 2011; 131:260–261.

28. Brissos S, Veguilla MR, Taylor D, Balanza-Martinez V. The role of longacting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol. 2014; 4:198–219.

29. Zhornitsky S, Stip E. Oral versus long-acting injectable antipsychotics in the treatment of schizophrenia and special populations at risk for treatment nonadherence: a systematic review. Schizophr Res Treatment. 2012; 2012:407171.

30. Iyer S, Banks N, Roy MA, Tibbo P, Williams R, Manchanda R, et al. A qualitative study of experiences with and perceptions regarding longacting injectable antipsychotics: part I-patient perspectives. Can J Psychiatry. 2013; 58:5 Suppl 1. 14S–22S.

31. Subotnik KL, Casaus LR, Ventura J, Luo JS, Hellemann GS, Gretchen-Doorly D, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A randomized clinical trial. JAMA Psychiatry. 2015; 72:822–829.

32. Schreiner A, Aadamsoo K, Altamura AC, Franco M, Gorwood P, Neznanov NG, et al. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophr Res. 2015; 169:393–399.

33. Gentile S. Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review. Pharmacotherapy. 2013; 33:1087–1106.

34. Hamer J, Norman TR, Kanaan R. One-year treatment continuation in patients switched to paliperidone palmitate: a retrospective study. J Clin Psychiatry. 2014; 75:1267–1269.

35. Malla A, Tibbo P, Chue P, Levy E, Manchanda R, Teehan M, et al. Long-acting injectable antipsychotics: recommendations for clinicians. Can J Psychiatry. 2013; 58:5 Suppl 1. 30S–35S.

36. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013; 382:951–962.

37. Misawa F, Kishimoto T, Hagi K, Kane JM, Correll CU. Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics. Schizophr Res. 2016; 176:220–230.

38. Uchida H, Suzuki T. Dose and dosing frequency of long-acting injectable antipsychotics: a systematic review of PET and SPECT data and clinical implications. J Clin Psychopharmacol. 2014; 34:728–735.

39. Seeman P, Seeman MV. Schizophrenia and the supersensitive synapse. Neuropsychiatry. 2011; 1:233–242.

40. Kimura H, Kanahara N, Komatsu N, Ishige M, Muneoka K, Yoshimura M, et al. A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis. Schizophr Res. 2014; 155:52–58.

41. Muller P, Seeman P. Presynaptic subsensitivity as a possible basis for sensitization by long-term dopamine mimetics. Eur J Pharmacol. 1979; 55:149–157.

42. Sreeraj VS, Shivakumar V, Rao NP, Venkatasubramanian G. A critical appraisal of long acting injectable antipsychotics: translating research to clinics. Asian J Psychiatr. 2017; 28:57–64.

43. Morrissette DA, Stahl SM. Optimizing outcomes in schizophrenia: longacting depots and long-term treatment. CNS Spectr. 2012; 17:10–21.

44. Patel MX, Taylor M, David AS. Antipsychotic long-acting injections: mind the gap. Br J Psychiatry Suppl. 2009; 52:S1–S4.

45. Valenstein M, Blow FC, Copeland LA, McCarthy JF, Zeber JE, Gillon L, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull. 2004; 30:255–264.

46. De Hert M, Sermon J, Geerts P, Vansteelandt K, Peuskens J, Detraux J. The use of continuous treatment versus placebo or intermittent treatment strategies in stabilized patients with schizophrenia: a systematic review and meta-analysis of randomized controlled trials with first-and second-generation antipsychotics. CNS Drugs. 2015; 29:637–658.

47. Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first episode schizophrenia. Arch Gen Psychiatry. 2011; 68:128–137.

48. Haijma SV, Van Haren N, Cahn W, Koolschijn PC, Hulshoff Pol HE, Kahn RS. Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects. Schizophr Bull. 2013; 39:1129–1138.

49. Bartzokis G, Lu PH, Raven EP, Amar CP, Detore NR, Couvrette AJ, et al. Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia. Schizophr Res. 2012; 140:122–128.

50. Heres S, Reichhart T, Hamann J, Mendel R, Leucht S, Kissling W. Psychiatrists' attitudeto antipsychotic depot treatment in patients with first-episode schizophrenia. Eur Psychiatry. 2011; 26:297–301.

51. Patel MX, Nikolaou V, David AS. Psychiatrists' attitudes to maintenance medicationfor patients with schizophrenia. Psychol Med. 2003; 33:83–89.

52. Patel MX, DE Zoysa N, Baker D, David AS. Antipsychotic depot medicationand attitudes of community psychiatric nurses. J Psychiatr Ment Health Nurs. 2005; 12:237–244.

53. Iyer S, Banks N, Roy MA, Tibbo P, Williams R, Manchanda R, et al. A qualitative study of experiences with and perceptions regarding longacting injectable antipsychotics: part II-physician perspectives. Can J Psychiatry. 2013; 58:5 Suppl 1. 23S–29S.

54. Hamann J, Mendel R, Heres S, Leucht S, Kissling W. How much more effective do depotantipsychotics have to be compared to oral antipsychotics before they are prescribed? Eur Neuropsychopharmacol. 2010; 20:276–279.

55. Heres S, Hamann J, Kissling W, Leucht S. Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry. 2006; 67:1948–1953.

56. Patel MX, Haddad PM, Chaudhry IB, McLoughlin S, Husain N, David AS. Psychiatrists' use, knowledge and attitudesto first- and second-generation antipsychotic long-acting injections: comparisons over 5 years. J Psychopharmacol. 2010; 24:1473–1482.

57. Weiden PJ, Roma RS, Velligan DI, Alphs L, DiChiara M, Davidson B. The challenge of offering long-acting antipsychotic therapies: a preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophrenia. J Clin Psychiatry. 2015; 76:684–690.

58. Carpenter WT Jr, Buchanan RW. Expanding therapy with long-acting antipsychotic medication in patients with schizophrenia. JAMA Psychiatry. 2015; 72:745–746.

59. Salgueiro M, Segarra R. Long-acting injectable second-generation antipsychotics in first-episode psychosis: a narrative review. Int Clin Psychopharmacol. 2019; 34:51–56.

60. Agid O, Schulze L, Arenovich T, Sajeev G, McDonald K, Foussias G, et al. Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching. Eur Neuropsychopharmacol. 2013; 23:1017–1022.

61. Suzuki T. A further consideration on long-acting injectable versus oral antipsychotics in the treatment of schizophrenia: a narrative review and critical appraisal. Expert Opin Drug Deliv. 2016; 13:253–264.

62. Bruijnzeel D, Suryadevara U, Tandon R. Antipsychotic treatment of schizophrenia: an update. Asian J Psychiatr. 2014; 11:3–7.